Zymeworks (ZYME) Net Income towards Common Stockholders (2021 - 2025)
Zymeworks' Net Income towards Common Stockholders history spans 5 years, with the latest figure at -$41.2 million for Q4 2025.
- On a quarterly basis, Net Income towards Common Stockholders fell 75.31% to -$41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$81.1 million, a 33.88% increase, with the full-year FY2025 number at -$81.1 million, up 33.88% from a year prior.
- Net Income towards Common Stockholders hit -$41.2 million in Q4 2025 for Zymeworks, down from -$19.6 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for ZYME hit a ceiling of $309.4 million in Q4 2022 and a floor of -$72.6 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$16.5 million across 5 years, with a median of -$30.8 million in 2024.
- Biggest five-year swings in Net Income towards Common Stockholders: skyrocketed 890.33% in 2022 and later plummeted 104.68% in 2023.
- Tracing ZYME's Net Income towards Common Stockholders over 5 years: stood at -$39.2 million in 2021, then skyrocketed by 890.33% to $309.4 million in 2022, then plummeted by 104.68% to -$14.5 million in 2023, then crashed by 62.31% to -$23.5 million in 2024, then tumbled by 75.31% to -$41.2 million in 2025.
- Business Quant data shows Net Income towards Common Stockholders for ZYME at -$41.2 million in Q4 2025, -$19.6 million in Q3 2025, and $2.3 million in Q2 2025.